Chimeric antigen receptor T-cell (CAR-T) therapy has gained momentum after the FDA approval of a CD19-targeted CAR-T-cell for treating acute lymphoblastic leukaemia in 2017. Here, CD19 is linked to acute lymphoblastic leukemia.